Developer docs
API playgroundTry for free, no card

Search company profiles

Bonafide Health

Full company profile

uuid0000a93

Namestring
Bonafide Health
Legal namestring
Bonafide Health, LLC
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Bonafide Health is a US-based women's healthcare company that develops, manufactures, and sells clinically studied, hormone-free supplements and a Class II medical device targeting menopause and perimenopause symptoms. Founded in 2011 and headquartered in Harrison, New York, the company was acquired by Pharmavite LLC — itself a portfolio company of Japan's Otsuka Pharmaceutical — in November 2023 for $425 million, providing it with capital, manufacturing scale, and retail distribution leverage. Bonafide's product portfolio is anchored by Revaree (an FDA-cleared hyaluronic acid vaginal insert for vaginal dryness, ranked #1 by gynecologists in a 2026 survey of 600 physicians), Thermella (a patented NKB-blocking supplement for hot flashes and night sweats, protected under US Patent 11,779,627), Clairvee (an acid-resistant delayed-release probiotic), Ristela (sexual satisfaction), Serenol (mood relief), Noctera (a February 2026 sleep supplement targeting GABAergic and glutamate pathways), and the Silvessa System (hair and skin). The portfolio is protected by 12+ US patents and supported by 40+ clinical studies.

Bonafide operates a multi-channel go-to-market. The primary channel is direct-to-consumer e-commerce through hellobonafide.com, with subscription pricing offering 20–50% discounts versus one-time purchase and free shipping on subscription orders. In September 2025 the company expanded into mainstream retail through Target (1,800+ stores and Target.com), and supplements this with Amazon marketplace distribution. Products are also HSA/FSA eligible through a Truemed partnership, reducing consumer out-of-pocket cost by approximately 30%. Subscription tiers range from roughly $29 to $77 per month across the product line.

The company's customer base is entirely consumer — women experiencing menopause, perimenopause, and PMS symptoms — with 1.5M+ lifetime customers and endorsement from 13,000+ physicians. Marketing is built around clinical evidence, healthcare-professional recommendations, content marketing via a Resource Center blog, social channels (Instagram, Facebook, TikTok, YouTube, Pinterest), and PR placements in outlets including the New York Times, Good Morning America, Allure, and Memorial Sloan Kettering. The company is privately held and operates under the Pharmavite / Otsuka corporate umbrella, with no public revenue disclosures available.

Short descriptiontext

Bonafide Health is a US women's healthcare company that develops and sells clinically studied, hormone-free supplements and an FDA-cleared vaginal insert for menopause and perimenopause symptoms. It sells through DTC subscriptions, Target retail, and Amazon.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHarrison, United States
HQ citystring
Harrison
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
women's health supplements, menopause symptom relief, hormone-free therapeutics, nutraceutical products, vaginal health care
Industry3 codes
1Vaginal Moisturizers & Lubricants
CodeCRABAIAIPrimaryYes
2Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
CodeHLAIAAAJPrimaryNo
3Sleep, Stress & Mood Support
CodeHLAIADAGPrimaryNo
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Women's Health & Menopause Nutraceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Direct-to-Consumer Product Sales
TypeSubscription Recurring
Description

Primary revenue stream through the company's e-commerce website with subscription model offering 20-50% discounts on monthly plans. One-time purchases also available at higher price points. Subscription customers receive free shipping.

hellobonafide.com
2Retail Distribution
TypeSubscription Recurring
Description

Products sold through Target retail stores (1,800+ locations) and Target.com as part of retail expansion strategy under parent company Pharmavite.

globenewswire.com
3Marketplace Sales
TypeOne Time License
Description

Products available on Amazon marketplace, particularly for Noctera launch and other supplements.

hellobonafide.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D, Infrastructure
Pricing details10 tiers
1Noctera Sleep Supplement - From $29.99/mo subscription
ModelSubscriptionBilling cadenceMonthly
Notes

Monthly plan: $33.99/mo; 3-month plan: $29.99/mo; One-time: $44.99

hellobonafide.com
2Revaree Vaginal Dryness Relief - From $37/mo subscription
ModelSubscriptionBilling cadenceMonthly
Notes

Monthly plan: $47/mo; 3-month plan: $43/mo (save 31%); 6-month plan: $37/mo (save 41%); One-time box: $63 + $5 shipping

hellobonafide.com
3Thermella Hot Flash Relief - From $35/mo subscription
ModelSubscriptionBilling cadenceMonthly
Notes

Monthly plan: $45/mo; 3-month plan: $40/mo (save 33%); 6-month plan: $35/mo (save 33%); One-time: $60 + $5 shipping

hellobonafide.com
4Ristela Sexual Satisfaction - From $43/mo subscription
ModelSubscriptionBilling cadenceMonthly
Notes

Monthly plan: $58/mo; 3-month plan: $58/mo (save 25%); 6-month plan: $43/mo; One-time: $58 + $5 shipping

hellobonafide.com
5Serenol Mood Relief - From $48/mo subscription
ModelSubscriptionBilling cadenceMonthly
Notes

Monthly plan: $48/mo; One-time: pricing varies

hellobonafide.com
6Clairvee Probiotic - From $35/mo subscription
ModelSubscriptionBilling cadenceMonthly
Notes

Monthly plan: $39/mo (save 29%); 3-month plan: $35/mo (save 36%); One-time: $55 + $5 shipping

hellobonafide.com
7Revaree Plus Extra-Strength - From $41/mo subscription
ModelSubscriptionBilling cadenceMonthly
Notes

Monthly plan: $52/mo; 3-month plan: $47/mo (save 27%); 6-month plan: $41/mo (save 27%); One-time: $65 + $5 shipping

hellobonafide.com
8Silvessa System - From $72/mo subscription
ModelSubscriptionBilling cadenceMonthly
Notes

Monthly plan: $76.50/mo; 3-month plan: $72/mo (save 42%); One-time: $126 + $5 shipping

hellobonafide.com
9Relizen Hot Flash Relief - From $33/mo subscription
ModelSubscriptionBilling cadenceMonthly
Notes

Monthly plan: $42/mo; 3-month plan: $38/mo (save 34%); 6-month plan: $33/mo (save 43%)

hellobonafide.com
10Silvessa Oral Capsule - From $28/mo subscription
ModelSubscriptionBilling cadenceMonthly
Notes

Monthly plan: $34/mo; 3-month plan: $32/mo (save 23%); 6-month plan: $28/mo; One-time: $42 + $5 shipping

hellobonafide.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1Revaree
Description

Hyaluronic acid vaginal insert for vaginal dryness relief

hellobonafide.com
+7 more records
Core offering1 text field

Bonafide Health develops, manufactures, and sells clinically studied, hormone-free dietary supplements and a Class II medical device (hyaluronic acid vaginal insert) addressing perimenopause and menopause symptoms including vaginal dryness, hot flashes, night sweats, sleep disruption, mood swings, low sexual arousal, and estrogen-related hair and skin changes. Products are sold primarily through the company's DTC e-commerce site with a subscription model, plus Target retail and Amazon, with strong physician endorsement positioning.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 11 values shown
  • 91% of women experienced symptom improvement with Revaree (vaginal dryness)
+10 more records
Product overview1 text field

Bonafide Health is a women's healthcare company offering a portfolio of clinically studied, hormone-free supplements for menopause symptoms and women's health issues. The product lineup centers on five core symptom-relief products: Revaree/Revaree Plus (hyaluronic acid vaginal inserts for dryness), Noctera (sleep support), Thermella (hot flash relief), Clairvee Probiotic (vaginal microbiome balance), Ristela/Ristela Mixes (sexual satisfaction), and Serenol (mood swing relief). The company also offers the Silvessa System (oral capsule, hair serum, and skin serum) for estrogen-decline-related hair and skin changes, plus general wellness products (Multi Vitamin, Gut Probiotic). Products are available via direct-to-consumer subscription through the company website and Amazon, with retail expansion into Target stores. The company emphasizes clinically validated, hormone-free formulations and reports being trusted by 13,000+ doctors.

Product and service1 record
1Revaree
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-01
Description

Bonafide launched four women's health products in over 1,800 Target stores and Target.com, marking the company's first major retail expansion. Products include hormone-free solutions for menopause symptoms.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Truemed partnership enables Bonafide customers to purchase products using HSA/FSA funds. Customers complete a brief health survey, and upon approval receive a Letter of Medical Necessity for reimbursement or direct purchase with HSA/FSA cards.

3Dr. Alyssa Dweck, MS, MD, FACOG, MSCP
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Alyssa Dweck serves as Chief Medical Officer of Bonafide Health. She conducts satellite media tours and educational initiatives about menopause and perimenopause symptoms and solutions.

hellobonafide.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Estroven is a long-standing, mass-market menopause supplement brand (owned by i-Health) selling non-prescription products targeting hot flashes, night sweats, and hormonal balance. Directly comparable to Bonafide in category, target customer (women in perimenopause/menopause), and OTC distribution model.

2Pause
TypeDirect peer
Description

Pause is a venture-backed DTC women's wellness brand focused on menopause symptoms (hot flashes, sleep, mood, libido). Highly comparable to Bonafide as a digitally native, science-led menopause brand targeting the same primary demographic with subscription-based products.

TypeDirect peer
Description

Amberen is a menopause supplement brand offering non-hormonal capsules for hot flashes, night sweats, mood, and sleep. Directly overlaps with Bonafide in mechanism (non-hormonal), indication (menopause symptom relief), and channel (DTC plus mass-market retail).

TypeDirect peer
Description

Replens is a leading over-the-counter vaginal moisturizer brand (Church & Dwight) using bioadhesive/hydrating technology for vaginal dryness. Directly comparable to Bonafide's Revaree and Revaree Plus hyaluronic acid vaginal inserts, addressing the same indication in the same demographic.

TypeDirect peer
Description

Hyalo-Gyn is a hyaluronic acid-based vaginal moisturizer sold OTC for vaginal dryness and intimate comfort. A direct, single-product competitor to Revaree in the hyaluronic acid vaginal insert category Bonafide has been ranked #1 in by gynecologists.

TypeDirect peer
Description

Equelle is an OTC menopause supplement brand built around S-equol for hot flashes and other menopausal symptoms. Directly comparable to Bonafide's Thermella in mechanism (non-hormonal supplement targeting menopausal relief) and target consumer.

TypeBroad incumbent
Description

Ritual is a digitally native vitamins and supplements brand with a women's health focus and subscription model. Comparable to Bonafide in DTC/subscription GTM, premium positioning, and clean-label supplement ethos, though not menopause-specialized.

8Care/of
TypeBroad incumbent
Description

Care/of is a personalized DTC vitamin and supplement subscription brand. Comparable to Bonafide in subscription-based DTC supplement business model and target demographics (women's health/wellness), though it is broader across nutritional supplements rather than menopause-specialized.

TypeBroad incumbent
Description

Metagenics is a practitioner-grade nutritional supplement company with a women's health portfolio including menopause-targeted products. Comparable to Bonafide in clinically studied nutraceuticals and physician-channel marketing, with broader nutritional supplement scope.

TypeOthers
Description

Oura is a women's health-focused smart ring maker that has increasingly targeted perimenopause/menopause monitoring and women's hormonal health features. Adjacent rather than direct: comparable target demographic and growing menopause-health association, but not a supplement/OTC product competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bonafide Health

Women's Health & Menopause Nutraceuticalshellobonafide.com

Bonafide Health is a US women's healthcare company that develops and sells clinically studied, hormone-free supplements and an FDA-cleared vaginal insert for menopause and perimenopause symptoms. It sells through DTC subscriptions, Target retail, and Amazon.

What Bonafide Health does

Bonafide Health is a US-based women's healthcare company that develops, manufactures, and sells clinically studied, hormone-free supplements and a Class II medical device targeting menopause and perimenopause symptoms. Founded in 2011 and headquartered in Harrison, New York, the company was acquired by Pharmavite LLC — itself a portfolio company of Japan's Otsuka Pharmaceutical — in November 2023 for $425 million, providing it with capital, manufacturing scale, and retail distribution leverage. Bonafide's product portfolio is anchored by Revaree (an FDA-cleared hyaluronic acid vaginal insert for vaginal dryness, ranked #1 by gynecologists in a 2026 survey of 600 physicians), Thermella (a patented NKB-blocking supplement for hot flashes and night sweats, protected under US Patent 11,779,627), Clairvee (an acid-resistant delayed-release probiotic), Ristela (sexual satisfaction), Serenol (mood relief), Noctera (a February 2026 sleep supplement targeting GABAergic and glutamate pathways), and the Silvessa System (hair and skin). The portfolio is protected by 12+ US patents and supported by 40+ clinical studies.

Bonafide operates a multi-channel go-to-market. The primary channel is direct-to-consumer e-commerce through hellobonafide.com, with subscription pricing offering 20–50% discounts versus one-time purchase and free shipping on subscription orders. In September 2025 the company expanded into mainstream retail through Target (1,800+ stores and Target.com), and supplements this with Amazon marketplace distribution. Products are also HSA/FSA eligible through a Truemed partnership, reducing consumer out-of-pocket cost by approximately 30%. Subscription tiers range from roughly $29 to $77 per month across the product line.

The company's customer base is entirely consumer — women experiencing menopause, perimenopause, and PMS symptoms — with 1.5M+ lifetime customers and endorsement from 13,000+ physicians. Marketing is built around clinical evidence, healthcare-professional recommendations, content marketing via a Resource Center blog, social channels (Instagram, Facebook, TikTok, YouTube, Pinterest), and PR placements in outlets including the New York Times, Good Morning America, Allure, and Memorial Sloan Kettering. The company is privately held and operates under the Pharmavite / Otsuka corporate umbrella, with no public revenue disclosures available.

Bonafide Health firmographics

Firmographics
Name
Bonafide Health
Legal name
Bonafide Health, LLC
Website
https://hellobonafide.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
101–250 employees
Short description
Bonafide Health is a US women's healthcare company that develops and sells clinically studied, hormone-free supplements and an FDA-cleared vaginal insert for menopause and perimenopause symptoms. It sells through DTC subscriptions, Target retail, and Amazon.
Ownership category
akta.pro rank

Bonafide Health industry classification

Industry
Product category
Women's Health & Menopause Nutraceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro primary industry
Vaginal Moisturizers & Lubricants (CRABAIAI)
akta.pro secondary industries
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Sleep, Stress & Mood Support (HLAIADAG)

Keywords

  • Women's health supplements
  • Menopause symptom relief
  • Hormone-free therapeutics
  • Nutraceutical products
  • Vaginal health care

Where Bonafide Health is headquartered

Location

Headquarters

HQ city
Harrison
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Bonafide Health business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D, Infrastructure

Revenue model

  1. Direct-to-Consumer Product Sales: Primary revenue stream through the company's e-commerce website with subscription model offering 20-50% discounts on monthly plans. One-time purchases also available at higher price points. Subscription customers receive free shipping.
  2. Retail Distribution: Products sold through Target retail stores (1,800+ locations) and Target.com as part of retail expansion strategy under parent company Pharmavite.
  3. Marketplace Sales: Products available on Amazon marketplace, particularly for Noctera launch and other supplements.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyNoctera Sleep Supplement - From $29.99/mo subscription
SubscriptionMonthlyRevaree Vaginal Dryness Relief - From $37/mo subscription
SubscriptionMonthlyThermella Hot Flash Relief - From $35/mo subscription
SubscriptionMonthlyRistela Sexual Satisfaction - From $43/mo subscription
SubscriptionMonthlySerenol Mood Relief - From $48/mo subscription
SubscriptionMonthlyClairvee Probiotic - From $35/mo subscription
SubscriptionMonthlyRevaree Plus Extra-Strength - From $41/mo subscription
SubscriptionMonthlySilvessa System - From $72/mo subscription
SubscriptionMonthlyRelizen Hot Flash Relief - From $33/mo subscription
SubscriptionMonthlySilvessa Oral Capsule - From $28/mo subscription

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Bonafide Health product offering

Product offering

Core offering

Bonafide Health develops, manufactures, and sells clinically studied, hormone-free dietary supplements and a Class II medical device (hyaluronic acid vaginal insert) addressing perimenopause and menopause symptoms including vaginal dryness, hot flashes, night sweats, sleep disruption, mood swings, low sexual arousal, and estrogen-related hair and skin changes. Products are sold primarily through the company's DTC e-commerce site with a subscription model, plus Target retail and Amazon, with strong physician endorsement positioning.

Product overview

Bonafide Health is a women's healthcare company offering a portfolio of clinically studied, hormone-free supplements for menopause symptoms and women's health issues. The product lineup centers on five core symptom-relief products: Revaree/Revaree Plus (hyaluronic acid vaginal inserts for dryness), Noctera (sleep support), Thermella (hot flash relief), Clairvee Probiotic (vaginal microbiome balance), Ristela/Ristela Mixes (sexual satisfaction), and Serenol (mood swing relief). The company also offers the Silvessa System (oral capsule, hair serum, and skin serum) for estrogen-decline-related hair and skin changes, plus general wellness products (Multi Vitamin, Gut Probiotic). Products are available via direct-to-consumer subscription through the company website and Amazon, with retail expansion into Target stores. The company emphasizes clinically validated, hormone-free formulations and reports being trusted by 13,000+ doctors.

Differentiator

Problem solved

Functional benefit

Brands

  • Revaree: Hyaluronic acid vaginal insert for vaginal dryness relief
  • Noctera
  • Thermella
  • Clairvee
  • Ristela
  • Serenol
  • Silvessa
  • Relizen

Products and services

  • Revaree

Quantifiable outcome

  • 91% of women experienced symptom improvement with Revaree (vaginal dryness)
  • +10 more outcomes

Companies that use Bonafide Health

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Bonafide Health technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Bonafide Health partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • TargetflagshipChannel Partner/ Reseller/ Distributor · 1 September 2025Bonafide launched four women's health products in over 1,800 Target stores and Target.com, marking the company's first major retail expansion. Products include hormone-free solutions for menopause symptoms.
  • TruemedcoreGTM or Marketing PartnerTruemed partnership enables Bonafide customers to purchase products using HSA/FSA funds. Customers complete a brief health survey, and upon approval receive a Letter of Medical Necessity for reimbursement or direct purchase with HSA/FSA cards.
  • Dr. Alyssa Dweck, MS, MD, FACOG, MSCPcoreStrategic or Co-development PartnerDr. Alyssa Dweck serves as Chief Medical Officer of Bonafide Health. She conducts satellite media tours and educational initiatives about menopause and perimenopause symptoms and solutions.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Bonafide Health competitors and assessment

Company assessment

Direct peers

  • Estroven: Estroven is a long-standing, mass-market menopause supplement brand (owned by i-Health) selling non-prescription products targeting hot flashes, night sweats, and hormonal balance. Directly comparable to Bonafide in category, target customer (women in perimenopause/menopause), and OTC distribution model.
  • Pause: Pause is a venture-backed DTC women's wellness brand focused on menopause symptoms (hot flashes, sleep, mood, libido). Highly comparable to Bonafide as a digitally native, science-led menopause brand targeting the same primary demographic with subscription-based products.
  • Amberen: Amberen is a menopause supplement brand offering non-hormonal capsules for hot flashes, night sweats, mood, and sleep. Directly overlaps with Bonafide in mechanism (non-hormonal), indication (menopause symptom relief), and channel (DTC plus mass-market retail).
  • Replens: Replens is a leading over-the-counter vaginal moisturizer brand (Church & Dwight) using bioadhesive/hydrating technology for vaginal dryness. Directly comparable to Bonafide's Revaree and Revaree Plus hyaluronic acid vaginal inserts, addressing the same indication in the same demographic.
  • Hyalo-Gyn: Hyalo-Gyn is a hyaluronic acid-based vaginal moisturizer sold OTC for vaginal dryness and intimate comfort. A direct, single-product competitor to Revaree in the hyaluronic acid vaginal insert category Bonafide has been ranked #1 in by gynecologists.
  • Equelle: Equelle is an OTC menopause supplement brand built around S-equol for hot flashes and other menopausal symptoms. Directly comparable to Bonafide's Thermella in mechanism (non-hormonal supplement targeting menopausal relief) and target consumer.

Broad incumbents

  • Ritual: Ritual is a digitally native vitamins and supplements brand with a women's health focus and subscription model. Comparable to Bonafide in DTC/subscription GTM, premium positioning, and clean-label supplement ethos, though not menopause-specialized.
  • Care/of: Care/of is a personalized DTC vitamin and supplement subscription brand. Comparable to Bonafide in subscription-based DTC supplement business model and target demographics (women's health/wellness), though it is broader across nutritional supplements rather than menopause-specialized.
  • Metagenics: Metagenics is a practitioner-grade nutritional supplement company with a women's health portfolio including menopause-targeted products. Comparable to Bonafide in clinically studied nutraceuticals and physician-channel marketing, with broader nutritional supplement scope.

Others

  • Oura: Oura is a women's health-focused smart ring maker that has increasingly targeted perimenopause/menopause monitoring and women's hormonal health features. Adjacent rather than direct: comparable target demographic and growing menopause-health association, but not a supplement/OTC product competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Bonafide Health social profiles

Digital presence

Bonafide Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bonafide Health leadership team

Management profile

Number of profiles

Profiles4 records

Bonafide Health funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bonafide Health M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bonafide Health

What does Bonafide Health do?

Bonafide Health develops, manufactures, and sells clinically studied, hormone-free dietary supplements and a Class II medical device (hyaluronic acid vaginal insert) addressing perimenopause and menopause symptoms including vaginal dryness, hot flashes, night sweats, sleep disruption, mood swings, low sexual arousal, and estrogen-related hair and skin changes. Products are sold primarily through the company's DTC e-commerce site with a subscription model, plus Target retail and Amazon, with strong physician endorsement positioning.

Is Bonafide Health a public or private company?

Bonafide Health is a private company. It is classified as corporate owned and is currently operating.

When was Bonafide Health founded?

Bonafide Health was founded in 2011. It employs 101 to 250 people.

Where is Bonafide Health based?

Bonafide Health is headquartered in Harrison, United States, in the North America region.

How does Bonafide Health make money?

Three revenue lines are on record. Direct-to-Consumer Product Sales are the primary driver. The others are retail Distribution and marketplace Sales.

Who are Bonafide Health's main competitors?

Direct peers on record are Estroven, Pause, Amberen, Replens, Hyalo-Gyn and Equelle. Broad incumbents are Ritual, Care/of and Metagenics. Oura is listed as an others.

Does Bonafide Health have an API?

No public API is recorded for Bonafide Health.

What industry is Bonafide Health in?

Bonafide Health's product category is Women's Health & Menopause Nutraceuticals. Its primary akta.pro industry code is CRABAIAI, Vaginal Moisturizers & Lubricants, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageBonafide Health Releases Sixth Annual State of Menopause™ ResultsBonafide Health released findings from its 6th Annual State of Menopause Survey, polling over 2,000 U.S. women ages 40-64 experiencing perimenopause or menopause symptoms. The survey found that cognitive and emotional symptoms (anxiety, brain fog, sleep disruption) are now more impactful than physical symptoms like hot flashes, with 60% reporting negative effects on mental health and 77% experiencing cognitive changes. Additionally, 56% said symptoms affect their work through declining motivation, 48% reported negative income impacts, and 23% lost at least $10,000 due to menopause symptoms.GlobeNewswireBonafide Health Releases Sixth Annual State of Menopause™ ResultsBonafide Health released findings from its 6th Annual State of Menopause Survey, surveying over 2,000 U.S. women ages 40-64 experiencing perimenopause or menopause symptoms. The survey found that cognitive and emotional symptoms such as anxiety, brain fog, and depression are now outweighing physical symptoms like hot flashes, with 60% of women reporting negative impacts on mental health and 56% citing declining motivation as the biggest workplace challenge. Nearly half (48%) of respondents said symptoms negatively affected their income, while only 7% of working women reported awareness of menopause workplace accommodations.BriefglanceThe Doctor's Seal: Decoding Bonafide's Menopause Market MilestoneBonafide Health announced that a national survey of 600 gynecologists named several of its products, including Revaree and Ristela, the top-recommended options in their respective categories for menopause symptom relief. The survey, conducted by Catapult Insights, found that Revaree ranked as the #1 gynecologist-recommended OTC hyaluronic acid insert for vaginal dryness, while 65% of women would not consider Hormone Replacement Therapy according to Bonafide's own research. The endorsements support Bonafide's strategy to expand from direct-to-consumer sales into mainstream retail chains like Target as part of its parent company Pharmavite's portfolio under Japan's Otsuka Pharmaceutical.openPR.comTop Players and Market Competition in the Uncomplicated Urinary Tract Infection Treatment SectorThe uncomplicated urinary tract infection treatment market is projected to grow to $10.52 billion by 2030 at a compound annual growth rate of 9.2%, driven by new antibiotic development, antimicrobial resistance efforts, and digital prescription tools. In a notable transaction, US-based dietary supplement company Pharmavite acquired Bonafide Health in November 2023 for $425 million to expand its product portfolio in the UTI supplement segment. In April 2024, UK biotechnology firm Utility Therapeutics Ltd. received FDA approval for Pivya (pivmecillinam), an aminopenicillin antibiotic for treating uncomplicated UTIs in adult women.NewBeautyThe New Era of Feminine Health Is Here, and These Are the Products Worth TryingThis article showcases the growing trend in feminine health products across period care, menopause care, and intimate care categories. Several OBGYNs attribute this surge in attention to policy decisions highlighting healthcare disparities for women and the historic lack of research in women's vaginal and sexual health. Featured brands include DIVA (Cramp Care Patch), Cora (Invisi-feel Daily Liner), LOLA (Compact Plastic Applicator Tampons), Alubri (Vaginal Moisturizing Gel), Bonafide Health (Thermella supplement), and Evvy (Estradiol Vaginal Cream), with quotes from executives and medical officers promoting their products.HomepageBonafide Health Launches Noctera, a Hormone-Free Sleep Supplement for Menopausal WomenBonafide Health has launched Noctera, a hormone-free, melatonin-free sleep supplement designed specifically for sleep disruptions experienced during the menopause transition. The supplement works through GABAergic and glutamate pathways and is backed by a randomized, double-blind, placebo-controlled clinical trial showing that 88% of participants moved to normal sleep disturbance levels within three weeks, with an average increase in sleep duration of 40 minutes. The company, which says it is trusted by more than 13,000 doctors, is positioning Noctera as part of a portfolio of clinically studied, hormone-free alternatives to hormone replacement therapy.GlobeNewswireSexual Health Supplement Market Report 2026-2035: Market to Reach $5.31 Billion by 2030, Driven by Biotechnology Innovation, Transparency in Ingredient Traceability and Gender-Specific ExpansionThe global sexual health supplement market is projected to grow from $3.44 billion in 2025 to $3.79 billion in 2026, reaching $5.31 billion by 2030, driven by consumer awareness, e-commerce proliferation, and demand for natural formulations. Pharmavite LLC acquired Bonafide Health for $425 million in November 2023 to expand its women's health portfolio, while Setu Nutrition partnered with MyMuse to launch Desire Boost Gummies targeting libido and energy. The Asia Pacific region led the market in 2025, with China, India, and Japan as significant contributors, as companies increasingly focus on personalized, plant-based supplements and innovative formats like functional gummies.YahooSexual Health Supplement Market Report 2026-2035: Market to Reach $5.31 Billion by 2030, Driven by Biotechnology Innovation, Transparency in Ingredient Traceability and Gender-Specific ExpansionA market research report projects the global sexual health supplement market will grow from $3.44 billion in 2025 to $5.31 billion by 2030, driven by increased consumer awareness, preventive health emphasis, and e-commerce expansion. The report highlights a notable strategic acquisition in November 2023, when Pharmavite LLC acquired Bonafide Health for $425 million to expand its women's health portfolio, along with partnerships such as Setu Nutrition's launch of Desire Boost Gummies with MyMuse. Key market trends include rising demand for natural and personalized products, innovative formats like functional gummies, and gender-specific supplements, with Asia Pacific representing the largest regional market.GlobeNewswireBonafide® Health Launches Noctera™ – A Novel, Hormone-FreeBonafide Health, a women's healthcare company, has launched Noctera, a hormone-free, prescription-free dietary supplement designed to improve sleep quality and duration in women experiencing menopausal sleep disruptions. The supplement targets GABAergic and Glutamate pathways in the brain, and a randomized double-blind placebo-controlled clinical trial demonstrated that 88% of women with moderate-to-severe sleep issues experienced reduced disturbances with an average increase of 40 minutes in sleep duration. The product is available online through the company's website and on Amazon, with monthly subscriptions starting at $33.99.YahooBonafide® Health Launches Noctera™ – A Novel, Hormone-Free Supplement Designed to Improve Sleep Quality and Duration Negatively Impacted by Hormonal ChangesBonafide Health has launched Noctera, a hormone-free, prescription-free supplement designed to improve sleep quality and duration for menopausal women. A randomized, double-blind, placebo-controlled clinical trial found that 88% of women experienced reduced sleep disturbances with an average increase of 40 minutes in sleep duration. Noctera is available online through the company's website and Amazon with monthly subscriptions starting at $33.99.